DK1321144T3 - Øjendråber - Google Patents

Øjendråber

Info

Publication number
DK1321144T3
DK1321144T3 DK01965597.6T DK01965597T DK1321144T3 DK 1321144 T3 DK1321144 T3 DK 1321144T3 DK 01965597 T DK01965597 T DK 01965597T DK 1321144 T3 DK1321144 T3 DK 1321144T3
Authority
DK
Denmark
Prior art keywords
prostaglandin derivatives
water
liable
ophthalmic solutions
eye drops
Prior art date
Application number
DK01965597.6T
Other languages
English (en)
Inventor
Kenji Morishima
Akio Kimura
Hiroyuki Asada
Masayuki Umeda
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co Ltd
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18762864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1321144(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Asahi Glass Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK1321144T3 publication Critical patent/DK1321144T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DK01965597.6T 2000-09-13 2001-09-13 Øjendråber DK1321144T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000277554 2000-09-13
PCT/JP2001/007928 WO2002022131A1 (fr) 2000-09-13 2001-09-13 Collyre

Publications (1)

Publication Number Publication Date
DK1321144T3 true DK1321144T3 (da) 2011-03-07

Family

ID=18762864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01965597.6T DK1321144T3 (da) 2000-09-13 2001-09-13 Øjendråber

Country Status (14)

Country Link
US (4) US20040097592A1 (da)
EP (1) EP1321144B1 (da)
KR (1) KR100854056B1 (da)
CN (1) CN1243548C (da)
AT (1) ATE490761T1 (da)
AU (1) AU2001286210A1 (da)
CA (1) CA2422031C (da)
CY (2) CY1113200T1 (da)
DE (1) DE60143615D1 (da)
DK (1) DK1321144T3 (da)
ES (1) ES2357551T3 (da)
NO (1) NO332650B1 (da)
PT (1) PT1321144E (da)
WO (1) WO2002022131A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
DK1532981T3 (da) * 2002-08-23 2008-01-28 Santen Pharmaceutical Co Ltd Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
DE602004023106D1 (de) * 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
WO2006068266A1 (ja) * 2004-12-24 2006-06-29 Santen Pharmaceutical Co., Ltd. プロスタグランジンＦ２ａ誘導体含有製品
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2006106915A1 (ja) 2005-03-31 2006-10-12 Asahi Glass Company, Limited プロスタグランジンＦ2α誘導体を有効成分として含む網膜神経細胞保護剤
JPWO2006112313A1 (ja) 2005-04-13 2008-12-11 宇部興産株式会社 インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
CN101400354B (zh) 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
FR2912207B1 (fr) * 2007-02-01 2012-10-26 Air Liquide Procede et appareil de production de monoxyde de carbone par distillation cryogenique
WO2008123396A1 (ja) * 2007-03-29 2008-10-16 Santen Pharmaceutical Co., Ltd. フルオロメトロンを含有する懸濁型点眼剤
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
WO2009131164A1 (ja) 2008-04-23 2009-10-29 大塚製薬株式会社 点眼剤及び使用方法
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20110136898A1 (en) * 2008-08-05 2011-06-09 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
CA2749352A1 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
ES2391721T3 (es) * 2010-03-01 2012-11-29 Laboratorios Salvat, S.A. Disoluciones acuosas transparentes de acetónido de fluocinolona para el tratamiento de la infamación de oído
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
WO2013183778A1 (ja) * 2012-06-08 2013-12-12 ライオン株式会社 粘膜用組成物
CN104288092A (zh) * 2013-07-16 2015-01-21 广东东阳光药业有限公司 拉坦前列素滴眼剂
CN104622798B (zh) * 2014-12-05 2017-12-22 广东东阳光药业有限公司 一种含有他氟前列素的滴眼液及其制备方法
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
EP3590513A4 (en) * 2017-02-28 2020-12-30 Kowa Company, Ltd. DRUG
ES2972844T3 (es) * 2017-03-27 2024-06-17 Alcon Inc Preparación farmacéutica
EA202190214A1 (ru) 2018-07-09 2021-04-16 Варшавске Закляды Фармацеутычне Польфа Са Офтальмологическое дозирующее устройство
CA3112278A1 (en) * 2018-09-21 2020-03-26 Ps Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
WO2020085812A1 (ko) 2018-10-25 2020-04-30 주식회사 넥스모스 압타민c를 유효성분으로 포함하는 점안액 조성물
CN115397392A (zh) * 2019-12-05 2022-11-25 Vanda制药公司 眼用药物组合物
US12357594B1 (en) 2021-06-30 2025-07-15 Sage Products, Llc Antimicrobial solution for pre-operative preparation
CN117180188B (zh) * 2023-08-24 2026-04-24 南京海纳制药有限公司 一种含有他氟前列素滴眼水性药物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
DE3850676T2 (de) * 1987-09-18 1994-11-03 Ueno Seiyaku Oyo Kenkyujo Kk Hypotensive okulare Mittel.
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JPH063800A (ja) * 1992-06-16 1994-01-14 Dainippon Screen Mfg Co Ltd 画像処理方法
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5486540A (en) * 1993-10-28 1996-01-23 Allergan, Inc. Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
JP3480549B2 (ja) * 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
AU778270C (en) * 1999-01-19 2005-07-21 Pharmacia & Upjohn Company Gamma-irradiation sterilized polyethylene packaging
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions

Also Published As

Publication number Publication date
US20180353518A1 (en) 2018-12-13
DE60143615D1 (de) 2011-01-20
CN1457256A (zh) 2003-11-19
PT1321144E (pt) 2011-03-10
NO20031138L (no) 2003-05-12
CA2422031A1 (en) 2003-03-12
CA2422031C (en) 2011-11-15
ES2357551T3 (es) 2011-04-27
CN1243548C (zh) 2006-03-01
US20160106757A1 (en) 2016-04-21
NO332650B1 (no) 2012-11-26
ATE490761T1 (de) 2010-12-15
CY1113200T1 (el) 2014-04-09
EP1321144A4 (en) 2009-07-29
CY2011007I1 (el) 2014-04-09
WO2002022131A1 (fr) 2002-03-21
AU2001286210A1 (en) 2002-03-26
CY2011007I2 (el) 2015-08-05
KR100854056B1 (ko) 2008-08-26
US20040097592A1 (en) 2004-05-20
KR20030029981A (ko) 2003-04-16
EP1321144A1 (en) 2003-06-25
US20070248697A1 (en) 2007-10-25
EP1321144B1 (en) 2010-12-08
NO20031138D0 (no) 2003-03-12

Similar Documents

Publication Publication Date Title
DK1321144T3 (da) Øjendråber
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
AU2001293851A1 (en) Stabilized hydrogen peroxide solutions
ES2085490T3 (es) Composiciones de tintas a base de agua.
CA2124873A1 (en) Iodine-containing corrosion inhibitor for oil field acidizing operations
DK1273299T3 (da) Minoxidilinindeholdende praparater
NO960062D0 (no) Farmasöytiske preparater for tungt opplöselige aktive midler
CA2260832A1 (en) Use of a combination of surfactants, chelating agents and essential oils for effective disinfection
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
MXPA04011914A (es) Formulacion farmaceutica de liberacion modificada.
TW266154B (da)
JPH09506518A (ja) 多価陽イオンキレート剤を用いて、アイケア用品における原生動物の増殖を抑制する方法
ES2108876T5 (es) Un procedimiento para la desinfeccion de lentes de contacto.
AR047279A1 (es) Composicion detergente liquida
BR0107716A (pt) Microemulsão herbicida
EP0497001A3 (en) Oxidized-type glutathione alkyl ester
IL111625A0 (en) Phosphoric esters for use as crystallisation inhibitors
EP0349153A3 (en) Stabilizing system for liquid hydrogen peroxide compositions and compositions so stabilized
DK1327453T3 (da) Stabile taurolidinelektrolytoplösninger
ATE180011T1 (de) Stabile flüssige reinigungsmittel, die pinienöl enthalten
AU2003298850A8 (en) Quaternary ammonium esters for disinfection and preservation
ES2076838T3 (es) Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.
EP1272655A4 (en) STABILIZATION OF HIGHLY SENSITIVE NUCLEIC ACID COLORS IN AQUEOUS SOLUTION
ES2166306B1 (es) Composicion desinfectante tensioactiva.
AU2001242398A1 (en) Contact lens treating method and composition